Aluminum in parenteral nutrition solution--sources and possible alternatives.

The extent of aluminum (Al) contamination in parenteral nutrition (PN) solutions for infants is not known. Aluminum was measured in 136 samples from various commercially available components that are used with PN. Results showed Al content varied widely among different components. The same chemical may have a different Al content depending on the manufacturer. However, Al contents were similar among lots from the same manufacturer for the same chemical. Aluminum contamination was arbitrarily classified as high (greater than 500 micrograms Al/liter), intermediate (51-500 micrograms Al/liter) or low (less than or equal to 50 micrograms Al/liter). The high group included most calcium and phosphorus containing salts, 1 multivitamin preparation, folic acid, ascorbic acid and concentrated (25%) albumin. The intermediate group included sodium lactate, potassium phosphates, zinc and chromium chloride, multitrace metal preparation, and 5% plasma protein. The low group included amino acids, sterile water and dextrose water, chloride salts of sodium, potassium, calcium, copper and chromium, sodium phosphates, magnesium sulphate, zinc sulphate, vitamin B12, vitamin K1, 1 multivitamin preparation, soybean oil emulsion and heparinized (2 U/ml) saline. PN solutions made from high Al components may contain up to 300 micrograms Al/liter. Calcium gluconate contributed greater than 80% of the total Al load from PN. Lowering of Al content in calcium gluconate in addition to use of specific low Al components offers the opportunity to significantly lower the Al concentration of the final PN solution and theoretically may achieve an Al content as low as 12 micrograms/l.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  F. A. de Wolff,et al.  Aluminum contamination of albumin-replacement solutions. , 1985, The New England journal of medicine.

[2]  A. Sedman,et al.  Evidence of aluminum loading in infants receiving intravenous therapy. , 1985, The New England journal of medicine.

[3]  D. Milliner,et al.  Inadvertent aluminum administration during plasma exchange due to aluminum contamination of albumin-replacement solutions. , 1985, The New England journal of medicine.

[4]  W. Goodman,et al.  Short-term aluminum administration in the rat. Effects on bone formation and relationship to renal osteomalacia. , 1984, The Journal of clinical investigation.

[5]  S. Ott,et al.  Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. , 1983, Annals of internal medicine.

[6]  R. Bertholf,et al.  Improved determination of aluminum in serum by electrothermal atomic absorption spectrophotometry. , 1983, Clinical chemistry.

[7]  P. Kostyniak An electrothermal atomic absorption method for aluminum analysis in plasma: identification of sources of contamination in blood sampling procedures. , 1983, Journal of analytical toxicology.

[8]  S. Ott,et al.  The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. , 1982, The New England journal of medicine.

[9]  J. Savory,et al.  The clinical biochemistry of aluminum. , 1981, Critical reviews in clinical laboratory sciences.

[10]  H. A. Ellis,et al.  Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation. , 1979, Journal of clinical pathology.

[11]  T. Feest,et al.  FRACTURING DIALYSIS OSTEODYSTROPHY AND DIALYSIS ENCEPHALOPATHY An Epidemiological Survey , 1979, The Lancet.

[12]  O. L. Kline,et al.  Commentary on breast-feeding and infant formulas, including proposed standards for formulas. , 1976, Pediatrics.